New hope for men with Tough-to-Treat prostate cancer and low blood counts
NCT ID NCT07025512
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This study tests a radioactive drug, 177Lu-PSMA-617, in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bone marrow, causing low blood cell counts. The goal is to see if the drug is safe and how it affects the cancer. About 40 adults will take part in this Phase 2 trial at M.D. Anderson Cancer Center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.